Drug name - Votrient

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7105530 NOVARTIS Pyrimidineamines as angiogenesis modulators
Oct, 2023

(1 year, 21 days from now)

CN1307173C NOVARTIS As A Phenyl-2-Pyrimidineamine Modulator Of Angiogenesis
Dec, 2021

(9 months ago)

CN1549813A NOVARTIS As A Phenyl-2-Pyrimidineamine Modulator Of Angiogenesis
Dec, 2021

(9 months ago)

IN200300818P2 NOVARTIS Pyrimidineamines As Angiogenesis Modulators
Dec, 2021

(9 months ago)

IN210284B NOVARTIS Pyrimidineamines As Angiogenesis Modulators
Dec, 2021

(9 months ago)

EP2311825A1 NOVARTIS Pyrimidineamines As Angiogenesis Modulators
Dec, 2021

(9 months ago)

EP2311825B1 NOVARTIS Pyrimidineamines As Angiogenesis Modulators
Dec, 2021

(9 months ago)

EP1343782B1 NOVARTIS Pyrimidineamines As Angiogenesis Modulators
Jun, 2025

(2 years from now)

EP1343782A1 NOVARTIS Pyrimidineamines As Angiogenesis Modulators
Jun, 2025

(2 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 200MG BASE TABLET;ORAL Prescription
EQ 400MG BASE TABLET;ORAL Discontinued

availability in other generic markets.

Click on the highlighted region to filter.